

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

**GRANT OF AWARDS UNDER
THE H SHARE AWARD AND TRUST SCHEME**

This announcement is made pursuant to Rules 17.06A, 17.06B and 17.06C of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the H Share Award and Trust Scheme (the “**Scheme**”) adopted by Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司) (the “**Company**”) by special resolution at its annual general meeting held on 16 May 2022. Under the Scheme, the Company has appointed Trident Trust Company (HK) Limited (the “**Trustee**”) to purchase H shares on the market using the Company’s funds at the then prevailing market prices and hold such shares in accordance with the rules of the Scheme for subsequent vesting to eligible grantees. The Scheme does not involve the issue of new shares.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) announces that on 28 June 2026, the Board (upon approval by the independent non-executive Directors pursuant to Rule 17.04(1) of the Listing Rules) resolved to grant a total of 33,400 H-share award shares to Dr. Liang Dongke under the Scheme (the “**Grant**”).

PARTICULARS OF THE GRANT

Pursuant to Rule 17.06B of the Listing Rules, particulars of the Grant are as follows:

- (1) Date of grant: 28 June 2026
- (2) Name of participant: Dr. Liang Dongke (an executive Director)
- (3) Number of award shares granted: 33,400 H shares, representing approximately 0.02% of the total 211,200,000 H shares in issue (excluding treasury shares) of the Company as at the date of this announcement
- (4) Purchase price of award shares: RMB24.61
- (5) Closing price of H shares prior to the date of grant (26 June 2026): HK\$30.68
- (6) Exercise period: Not applicable (the Grant comprises share awards and not share options)
- (7) Vesting period:

Vesting tranche	Vesting schedule	Vesting ratio
The first tranche	Expiration of 12 months from the date of grant	0%
The second tranche	Expiration of 24 months from the date of grant	30%
The third tranche	Expiration of 36 months from the date of grant	70%

- (8) Performance targets:

Pursuant to the rules of the Scheme, vesting of awards is subject to the assessment indicators and criteria of the Company and any other applicable vesting conditions set out in the award letter. The details of the assessment indicators of the Company shall be determined by the Board or its authorized persons from time to time with reference to the financial position (indicators such as revenue or net profit) of the Company, and shall be set out in the award letter. If a selected participant fails to satisfy the vesting conditions applicable to the grant of relevant awards, all award shares underlying the relevant awards shall not vest and shall be immediately forfeited.

(9) Clawback mechanism

Pursuant to Article 10 of the rules of the Scheme, the clawback arrangements applicable upon changes in circumstances of a selected participant are as follows:

- (a) If a selected participant undergoes a change of position but remains employed by the Group, or is rehired after retirement, any issued but unvested award shares shall continue to vest on the vesting dates specified in the award letter, unless otherwise determined by the Board or its authorized persons;
- (b) If a selected participant commits offences, breaches professional ethics, discloses confidential information of any members of the Group, harms the interests or reputation of any members of the Group through dereliction of duty or malpractice, or has their employment contract terminated due to any of the foregoing reasons and resulting in a change of position, the selected participant shall refund all proceeds derived from the vesting of the award shares to the Trust, such award shares shall become returned shares, and any issued but unvested award shares shall lapse with immediate effect;
- (c) If a selected participant ceases employment due to resignation, expiry of employment contract or redundancy by the Group, any issued but unvested award shares shall lapse with immediate effect, unless otherwise determined by the Board or its authorized persons;
- (d) If a selected participant retires upon reaching the statutory retirement age, any issued but unvested award shares shall lapse with immediate effect, unless otherwise determined by the Board or its authorized persons;
- (e) If a selected participant resigns due to loss of labor capacity caused by work-related injury or their employment contract with the Group is terminated for such reason, the issued but unvested award shares shall continue to vest on the vesting dates specified in the award letter, and the individual performance assessment criteria shall no longer apply as vesting conditions;
- (f) If a selected participant resigns due to loss of labor capacity caused by non-work-related injury or their employment contract with the Group is terminated for such reason, any issued but unvested award shares shall lapse with immediate effect, unless otherwise determined by the Board or its authorized persons;
- (g) If a selected participant passes away in the course of performing his/her duties, any issued but unvested award shares shall continue to vest on the vesting dates specified in the award letter; their legal representative or lawful successor shall be entitled to the award shares, and the individual performance assessment criteria shall no longer apply as vesting conditions;

- (h) If a selected participant passes away for other reasons, any issued but unvested award shares shall lapse with immediate effect on the date of their death, unless otherwise determined by the Board or its authorized persons; and
- (i) If a selected participant ceases to be an eligible employee for reasons other than those set out above, any issued but unvested award shares shall lapse with immediate effect, unless otherwise determined by the Board or its authorized persons.

In addition, pursuant to the rules of the Scheme, any granted but unvested awards shall not be transferred, pledged or mortgaged. The Board or its authorized persons may at their absolute discretion cancel any unvested or lapsed awards.

- (10) The Group has not provided any financial assistance to Dr. Liang Dongke for the purchase of shares under the Scheme.

NUMBER OF AWARD SHARES AVAILABLE FOR FUTURE GRANTS

Pursuant to Rule 17.06C of the Listing Rules, immediately following completion of the Grant, the number of award shares available for future grants under the Scheme shall be 4,323,000 H shares.

SOURCE OF AWARD SHARES

The award shares proposed to vest in Dr. Liang Dongke (subject to vesting conditions) shall be H shares purchased by the Trustee on the market under the Scheme as directed by the Board and/or its authorized persons. For the avoidance of doubt, no new H shares will be issued and allotted upon vesting and settlement of such award shares to Dr. Liang Dongke.

IMPLICATIONS UNDER THE LISTING RULES

Dr. Liang Dongke is the chairman and an executive Director of the Company and a connected person of the Company under Chapter 14A of the Listing Rules. As the grant of award shares to Dr. Liang Dongke forms part of his remuneration as set out in his service contract or letter of appointment (as the case may be) with the Company, the Grant is exempt from the reporting, announcement and independent shareholders' approval requirements pursuant to Rules 14A.73(6) and 14A.95 of the Listing Rules.

Pursuant to Rule 17.04(1) of the Listing Rules, the Grant has been approved by the Board (including independent non-executive Directors). Dr. Liang Dongke and Dr. Song Yuan have abstained from voting on the resolution concerning the Grant.

The Grant will not result in the aggregate number of shares issued and to be issued underlying all share options and share awards granted and to be granted to Dr. Liang Dongke within the 12-month period ending on and including the date of grant exceeding 0.1% of the total issued H shares (excluding treasury shares) of the Company (representing only approximately 0.02%). Accordingly, no shareholders' approval is required to be sought pursuant to Rule 17.04(2) of the Listing Rules.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
29 June 2026

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin and Mr. Zhang Hong as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

** For identification purposes only*